These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11936481)

  • 21. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
    Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
    Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS.
    Freedman MS; Brod S; Singer BA; Cohen BA; Hayward B; Dangond F; Coyle PK
    J Neurol; 2020 Jan; 267(1):64-75. PubMed ID: 31559532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
    Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
    Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
    Giovannoni G; Cohen JA; Coles AJ; Hartung HP; Havrdova E; Selmaj KW; Margolin DH; Lake SL; Kaup SM; Panzara MA; Compston DA;
    Neurology; 2016 Nov; 87(19):1985-1992. PubMed ID: 27733571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple sclerosis and depression: influence of interferon beta therapy.
    Zephir H; De Seze J; Stojkovic T; Delisse B; Ferriby D; Cabaret M; Vermersch P
    Mult Scler; 2003 Jun; 9(3):284-8. PubMed ID: 12814176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
    Rudick RA; Cookfair DL; Simonian NA; Ransohoff RM; Richert JR; Jacobs LD; Herndon RM; Salazar AM; Fischer JS; Granger CV; Goodkin DE; Simon JH; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munchsauer FE; O'Reilly K; Priore RL; Whitham RH
    J Neuroimmunol; 1999 Jan; 93(1-2):8-14. PubMed ID: 10378864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study.
    Clanet M; Kappos L; Hartung HP; Hohlfeld R;
    Mult Scler; 2004 Apr; 10(2):139-44. PubMed ID: 15124757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial.
    Lin X; Tench CR; Turner B; Blumhardt LD; Constantinescu CS
    J Neurol Neurosurg Psychiatry; 2003 Aug; 74(8):1090-4. PubMed ID: 12876240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE.
    Kieseier BC; Arnold DL; Balcer LJ; Boyko AA; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A; Sheikh SI; Calabresi PA
    Mult Scler; 2015 Jul; 21(8):1025-35. PubMed ID: 25432952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spotlight on subcutaneous recombinant interferon-beta-1a (Rebif) in relapsing-remitting multiple sclerosis.
    Murdoch D; Lyseng-Williamson KA
    BioDrugs; 2005; 19(5):323-5. PubMed ID: 16207073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical benefits of interferon beta-1a in relapsing-remitting MS: a phase IV study.
    Fernández O; Arbizu T; Izquierdo G; Martínez-Yélamos A; Gata JM; Luque G; de Ramón E
    Acta Neurol Scand; 2003 Jan; 107(1):7-11. PubMed ID: 12542507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
    Devonshire V; Havrdova E; Radue EW; O'Connor P; Zhang-Auberson L; Agoropoulou C; Häring DA; Francis G; Kappos L;
    Lancet Neurol; 2012 May; 11(5):420-8. PubMed ID: 22494956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS.
    Weinstock-Guttman B; Galetta SL; Giovannoni G; Havrdova E; Hutchinson M; Kappos L; O'Connor PW; Phillips JT; Polman C; Stuart WH; Lynn F; Hotermans C
    J Neurol; 2012 May; 259(5):898-905. PubMed ID: 22008873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis.
    Liu Y; Vollmer T; Havrdova E; Riester K; Lee A; Phillips G; Wang P; Sabatella G
    Mult Scler Relat Disord; 2017 Jan; 11():18-24. PubMed ID: 28104250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
    Cohen JA; Imrey PB; Calabresi PA; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Mandell BF; Scott TF; Zhang H; Apperson-Hansen C; Beck GJ; Houghtaling PL; Karafa MT; Stadtler M;
    Neurology; 2009 Feb; 72(6):535-41. PubMed ID: 19204263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy.
    Trojano M; Liguori M; Paolicelli D; Zimatore GB; De Robertis F; Avolio C; Giuliani F; Fuiani A; Livrea P;
    Mult Scler; 2003 Oct; 9(5):451-7. PubMed ID: 14582768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
    Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.